ISL
Ingalls & Snyder LLC’s Immunoprecise Antibodies IPA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.95M | Buy |
2,779,363
+21,236
| +0.8% | +$22.5K | 0.1% | 131 |
|
|
2025
Q1 | $1.04M | Buy |
2,758,127
+1,196,795
| +77% | +$450K | 0.03% | 211 |
|
|
2024
Q4 | $643K | Buy |
1,561,332
+2,440
| +0.2% | +$1.01K | 0.03% | 258 |
|
|
2024
Q3 | $996K | Buy |
1,558,892
+263,451
| +20% | +$168K | 0.04% | 218 |
|
|
2024
Q2 | $1.31M | Buy |
1,295,441
+6,906
| +0.5% | +$6.97K | 0.06% | 185 |
|
|
2024
Q1 | $1.96M | Buy |
1,288,535
+7,230
| +0.6% | +$11K | 0.09% | 146 |
|
|
2023
Q4 | $2.19M | Buy |
1,281,305
+253,052
| +25% | +$433K | 0.1% | 133 |
|
|
2023
Q3 | $1.88M | Sell |
1,028,253
-31,802
| -3% | -$58.2K | 0.09% | 146 |
|
|
2023
Q2 | $3.14M | Buy |
1,060,055
+2,020
| +0.2% | +$5.98K | 0.15% | 106 |
|
|
2023
Q1 | $2.93M | Buy |
1,058,035
+87,888
| +9% | +$243K | 0.15% | 101 |
|
|
2022
Q4 | $5.05M | Buy |
970,147
+3,057
| +0.3% | +$15.9K | 0.27% | 68 |
|
|
2022
Q3 | $3.86M | Buy |
967,090
+27,615
| +3% | +$110K | 0.22% | 78 |
|
|
2022
Q2 | $3.57M | Buy |
939,475
+7,275
| +0.8% | +$27.6K | 0.19% | 91 |
|
|
2022
Q1 | $4.79M | Buy |
932,200
+111,942
| +14% | +$575K | 0.21% | 87 |
|
|
2021
Q4 | $4.4M | Buy |
820,258
+198,811
| +32% | +$1.07M | 0.2% | 92 |
|
|
2021
Q3 | $3.87M | Buy |
621,447
+20,637
| +3% | +$128K | 0.18% | 105 |
|
|
2021
Q2 | $3.62M | Buy |
600,810
+83,615
| +16% | +$503K | 0.16% | 110 |
|
|
2021
Q1 | $5.08M | Buy |
517,195
+120,770
| +30% | +$1.19M | 0.24% | 80 |
|
|
2020
Q4 | $5.93M | Buy |
+396,425
| New | +$5.93M | 0.29% | 69 |
|